Symbols / XGN Stock $3.71 -6.78% Exagen Inc.

Healthcare • Diagnostics & Research • United States • NGM
XGN (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Diagnostics & Research
CEO Mr. John Aballi
Exch · Country NGM · United States
Market Cap 89.63M
Enterprise Value 95.00M
Income -20.17M
Sales 68.38M
FCF (ttm) —
Book/sh 0.76
Cash/sh 0.89
Employees 216
Insider 10d —
IPO Sep 19, 2019
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -8.24
PEG —
P/S 1.31
P/B 4.87
P/C —
EV/EBITDA -7.97
EV/Sales 1.39
Quick Ratio 2.97
Current Ratio 3.47
Debt/Eq 188.10
LT Debt/Eq —
EPS (ttm) -0.90
EPS next Y -0.45
EPS Growth —
Revenue Growth 11.70%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-04
Earnings (prior) 2026-05-11
ROA -19.13%
ROE -193.58%
ROIC —
Gross Margin 58.32%
Oper. Margin -19.73%
Profit Margin -29.49%
Shs Outstand 24.16M
Shs Float 16.23M
Insider Own 18.01%
Instit Own 58.98%
Short Float 3.31%
Short Ratio 3.81
Short Interest 724.68K
52W High 12.23
vs 52W High -69.66%
52W Low 2.59
vs 52W Low 43.24%
Beta —
Impl. Vol. 50.00%
Rel Volume 2.34
Avg Volume 374.29K
Volume 876.61K
Target (mean) $8.83
Tgt Median $8.50
Tgt Low $8.00
Tgt High $10.00
# Analysts 6
Recom Strong_buy
Prev Close $3.98
Price $3.71
Change -6.78%
About

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$8.83
Mean price target
2. Current target
$3.71
Latest analyst target
3. DCF / Fair value
$8.83
Proxy: analyst mean price target (no FCF/EPS data available).
Ratings
Current target
$3.71
Low
$8.00
High
$10.00
Mean
$8.83

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-12 main BTIG Buy → Buy $8
2026-04-20 main Canaccord Genuity Buy → Buy $8
2026-03-11 main Canaccord Genuity Buy → Buy $10
2026-03-11 main Craig-Hallum Buy → Buy $10
2026-03-11 main Keybanc Overweight → Overweight $10
2026-03-10 main BTIG Buy → Buy $9
2026-02-24 main TD Cowen Buy → Buy $10
2026-02-17 main BTIG Buy → Buy $10
2026-01-30 reit B. Riley Securities Buy → Buy $8
2025-11-10 main BTIG Buy → Buy $15
2025-11-05 reit B. Riley Securities Buy → Buy $18
2025-10-27 main Canaccord Genuity Buy → Buy $15
2025-10-22 main BTIG Buy → Buy $13
2025-10-14 main Keybanc Overweight → Overweight $15
2025-09-11 init B. Riley Securities — → Buy $15
2025-07-30 main Canaccord Genuity Buy → Buy $11
2025-07-30 up Keybanc Sector Weight → Overweight $12
2025-07-23 init Craig-Hallum — → Buy $12
2025-05-15 main Cantor Fitzgerald Overweight → Overweight $7
2025-05-13 main Canaccord Genuity Buy → Buy $8
News
RSS: Latest XGN news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-12 BLACK JEFFREY G Chief Financial Officer — 76,511 $3.08 $241,649
2026-03-12 ABALLI JOHN Chief Executive Officer — 150,000 $0.00 $0
2026-03-03 ABALLI JOHN Chief Executive Officer — 2,535 $3.08 $7,800
2026-03-03 ABALLI JOHN Chief Executive Officer — 15,698 $3.62 $56,827
2026-02-24 BLACK JEFFREY G Chief Financial Officer — 1,584 $3.61 $5,718
2026-02-24 ABALLI JOHN Chief Executive Officer — 11,430 $3.61 $41,262
2025-10-16 ABALLI JOHN Chief Executive Officer — 31,787 $11.82 $375,598
2025-09-02 BLACK JEFFREY G Chief Financial Officer — 20,466 $9.79 $200,362
2025-03-25 NMSIC CO-INVESTMENT FUND, L.P Beneficial Owner of more than 10% of a Class of Security — 350,000 $3.30 $1,155,000
2025-02-28 ABALLI JOHN Chief Executive Officer — 8,621 $3.46 $29,829
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
66.58
+19.65%
55.64
+5.89%
52.55
+15.33%
45.56
Operating Revenue
66.58
+19.65%
55.64
+5.89%
52.55
+15.33%
45.56
Cost Of Revenue
27.78
+23.29%
22.53
-2.44%
23.09
-4.63%
24.21
Reconciled Cost Of Revenue
27.78
+23.29%
22.53
-2.44%
23.09
-4.63%
24.21
Gross Profit
38.80
+17.18%
33.11
+12.41%
29.46
+37.97%
21.35
Operating Expense
52.87
+13.09%
46.75
-10.60%
52.29
-15.51%
61.89
Research And Development
6.25
+16.35%
5.38
+10.48%
4.87
-50.74%
9.88
Selling General And Administration
46.62
+12.67%
41.37
-12.77%
47.43
-8.82%
52.02
Total Expenses
80.64
+16.41%
69.28
-8.10%
75.39
-12.45%
86.11
Operating Income
-14.07
-3.18%
-13.64
+40.29%
-22.84
+43.67%
-40.55
Total Operating Income As Reported
-14.07
-3.18%
-13.64
+40.29%
-22.84
+50.41%
-46.05
EBITDA
-13.46
-20.81%
-11.14
+41.81%
-19.15
+56.14%
-43.66
Normalized EBITDA
-11.66
-4.65%
-11.14
+41.81%
-19.15
+49.81%
-38.16
Reconciled Depreciation
2.12
+22.85%
1.72
-20.48%
2.17
+39.24%
1.56
EBIT
-15.58
-21.08%
-12.87
+39.64%
-21.32
+52.85%
-45.22
Total Unusual Items
-1.80
0.00
0.00
+100.00%
-5.51
Total Unusual Items Excluding Goodwill
-1.80
0.00
0.00
+100.00%
-5.51
Special Income Charges
-0.29
0.00
0.00
+100.00%
-5.51
Other Special Charges
0.29
—
—
—
Impairment Of Capital Assets
—
—
0.00
-100.00%
5.51
Net Income
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Pretax Income
-19.90
-31.76%
-15.10
+36.16%
-23.66
+50.37%
-47.67
Net Non Operating Interest Income Expense
-4.03
-174.64%
-1.47
-79.12%
-0.82
+49.38%
-1.62
Interest Expense Non Operating
4.32
+93.29%
2.23
-4.33%
2.33
-4.62%
2.45
Net Interest Income
-4.03
-174.64%
-1.47
-79.12%
-0.82
+49.38%
-1.62
Interest Expense
4.32
+93.29%
2.23
-4.33%
2.33
-4.62%
2.45
Interest Income Non Operating
0.29
-62.32%
0.77
-49.41%
1.52
+82.65%
0.83
Interest Income
0.29
-62.32%
0.77
-49.41%
1.52
+82.65%
0.83
Other Income Expense
-1.80
—
—
-5.51
Other Non Operating Income Expenses
—
—
—
—
Gain On Sale Of Security
-1.51
—
—
—
Tax Provision
0.05
+325.00%
0.01
-63.64%
0.03
+111.70%
-0.28
Tax Rate For Calcs
0.00
+0.00%
0.00
+0.00%
0.00
+3400.00%
0.00
Tax Effect Of Unusual Items
-0.38
0.00
0.00
+100.00%
-0.03
Net Income Including Noncontrolling Interests
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Net Income From Continuing Operation Net Minority Interest
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Net Income From Continuing And Discontinued Operation
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Net Income Continuous Operations
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Normalized Income
-18.53
-22.58%
-15.12
+36.19%
-23.69
+43.48%
-41.91
Net Income Common Stockholders
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Diluted EPS
—
-0.83
+38.06%
-1.34
+51.62%
-2.77
Basic EPS
—
-0.83
+38.06%
-1.34
+51.62%
-2.77
Basic Average Shares
—
18.20
+2.96%
17.68
+3.50%
17.08
Diluted Average Shares
—
18.20
+2.96%
17.68
+3.50%
17.08
Diluted NI Availto Com Stockholders
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Line Item Trend 2023-12-31
Total Assets
56.94
Current Assets
47.84
Cash Cash Equivalents And Short Term Investments
36.49
Cash And Cash Equivalents
36.49
Receivables
6.55
Accounts Receivable
6.55
Gross Accounts Receivable
6.56
Allowance For Doubtful Accounts Receivable
-0.01
Prepaid Assets
2.87
Other Current Assets
1.93
Total Non Current Assets
9.10
Net PPE
8.49
Gross PPE
14.26
Accumulated Depreciation
-5.77
Properties
0.00
Buildings And Improvements
—
Machinery Furniture Equipment
2.28
Construction In Progress
0.06
Other Properties
8.60
Leases
3.32
Goodwill And Other Intangible Assets
—
Goodwill
—
Other Non Current Assets
0.62
Total Liabilities Net Minority Interest
34.25
Current Liabilities
11.90
Payables And Accrued Expenses
10.66
Payables
3.13
Accounts Payable
3.13
Current Accrued Expenses
7.53
Current Debt And Capital Lease Obligation
1.24
Current Debt
0.26
Other Current Borrowings
0.26
Current Capital Lease Obligation
0.98
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
0.30
Total Non Current Liabilities Net Minority Interest
22.35
Long Term Debt And Capital Lease Obligation
21.99
Long Term Debt
19.23
Long Term Capital Lease Obligation
2.76
Non Current Deferred Liabilities
—
Non Current Deferred Taxes Liabilities
—
Other Non Current Liabilities
0.36
Stockholders Equity
22.69
Common Stock Equity
22.69
Capital Stock
0.02
Common Stock
0.02
Preferred Stock
0.00
Share Issued
17.05
Ordinary Shares Number
17.05
Treasury Shares Number
0.00
Additional Paid In Capital
301.89
Retained Earnings
-279.22
Total Equity Gross Minority Interest
22.69
Total Capitalization
41.92
Working Capital
35.94
Invested Capital
42.19
Total Debt
23.23
Capital Lease Obligations
3.74
Net Tangible Assets
22.69
Tangible Book Value
22.69
Derivative Product Liabilities
—
Interest Payable
0.14
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.62
-2.61%
-13.28
+8.18%
-14.46
+55.01%
-32.14
Cash Flow From Continuing Operating Activities
-13.62
-2.61%
-13.28
+8.18%
-14.46
+55.01%
-32.14
Net Income From Continuing Operations
-19.95
-31.99%
-15.12
+36.19%
-23.69
+50.01%
-47.39
Depreciation Amortization Depletion
2.12
+22.85%
1.72
-20.48%
2.17
+39.24%
1.56
Depreciation And Amortization
2.12
+22.85%
1.72
-20.48%
2.17
+39.24%
1.56
Other Non Cash Items
2.23
+56.49%
1.43
-51.33%
2.93
+70.73%
1.72
Stock Based Compensation
2.16
+22.40%
1.76
-51.26%
3.62
-23.11%
4.70
Asset Impairment Charge
—
—
0.00
-100.00%
5.90
Deferred Tax
—
—
0.00
+100.00%
-0.31
Deferred Income Tax
—
—
0.00
+100.00%
-0.31
Operating Gains Losses
1.80
+1522.52%
0.11
-41.27%
0.19
—
Gain Loss On Investment Securities
1.51
—
—
—
Change In Working Capital
-1.98
+35.60%
-3.08
-1046.46%
0.33
-80.54%
1.67
Change In Receivables
-3.02
-135.20%
-1.28
-170.89%
-0.47
-113.25%
3.58
Changes In Account Receivables
-3.02
-135.20%
-1.28
-170.89%
-0.47
-113.25%
3.58
Change In Prepaid Assets
1.11
+162.00%
-1.79
-173.24%
-0.65
-29.50%
-0.51
Change In Payables And Accrued Expense
0.29
+67.43%
0.17
-93.17%
2.56
+611.78%
-0.50
Change In Accrued Expense
0.25
+288.72%
-0.13
-105.33%
2.50
+278.10%
-1.40
Change In Payable
0.04
-86.36%
0.31
+359.70%
0.07
-92.56%
0.90
Change In Account Payable
0.04
-86.36%
0.31
+359.70%
0.07
-92.56%
0.90
Change In Other Working Capital
-0.06
-107.91%
0.73
—
—
Change In Other Current Assets
0.79
+1157.14%
0.06
+162.38%
-0.10
-114.89%
-0.05
Change In Other Current Liabilities
-1.10
-12.30%
-0.98
+3.37%
-1.01
-18.27%
-0.85
Investing Cash Flow
-0.63
-21.55%
-0.52
+35.95%
-0.80
+81.38%
-4.32
Cash Flow From Continuing Investing Activities
-0.63
-21.55%
-0.52
+35.95%
-0.80
+81.38%
-4.32
Net PPE Purchase And Sale
-0.63
-21.55%
-0.52
+35.95%
-0.80
+81.38%
-4.32
Purchase Of PPE
-0.64
-24.47%
-0.52
+37.80%
-0.83
+80.82%
-4.32
Sale Of PPE
0.01
0.00
-100.00%
0.02
0.00
Capital Expenditure
-0.64
-24.47%
-0.52
+37.80%
-0.83
+80.82%
-4.32
Net Other Investing Changes
—
—
—
—
Financing Cash Flow
24.43
+3785.52%
-0.66
+93.76%
-10.63
-2074.23%
-0.49
Cash Flow From Continuing Financing Activities
24.43
+3785.52%
-0.66
+93.76%
-10.63
-2074.23%
-0.49
Net Issuance Payments Of Debt
2.88
+434.61%
-0.86
+92.13%
-10.94
-1471.55%
-0.70
Issuance Of Debt
23.67
0.00
—
—
Repayment Of Debt
-20.79
-2314.75%
-0.86
+92.13%
-10.94
-1471.55%
-0.70
Long Term Debt Issuance
23.67
0.00
—
—
Long Term Debt Payments
-20.79
-2314.75%
-0.86
+92.13%
-10.94
-1471.55%
-0.70
Net Long Term Debt Issuance
2.88
+434.61%
-0.86
+92.13%
-10.94
-1471.55%
-0.70
Net Common Stock Issuance
22.02
0.00
—
0.00
Proceeds From Stock Option Exercised
0.40
+101.01%
0.20
-35.29%
0.31
-31.39%
0.45
Net Other Financing Charges
-0.87
—
—
-0.24
Changes In Cash
10.18
+170.44%
-14.46
+44.18%
-25.90
+29.91%
-36.95
Beginning Cash Position
22.24
-39.40%
36.69
-41.38%
62.59
-37.12%
99.54
End Cash Position
32.42
+45.80%
22.24
-39.40%
36.69
-41.38%
62.59
Free Cash Flow
-14.27
-3.42%
-13.79
+9.78%
-15.29
+58.07%
-36.46
Interest Paid Supplemental Data
2.99
+73.76%
1.72
-1.04%
1.74
+0.29%
1.73
Income Tax Paid Supplemental Data
0.04
+9.38%
0.03
—
—
Common Stock Issuance
22.02
0.00
—
0.00
Issuance Of Capital Stock
22.02
0.00
—
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category